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The p53 tumor suppressor is recognized as a promising target for anti-cancer therapies. We previ-
ously reported that protoporphyrin IX (PpIX) disrupts the p53/murine double minute 2 (MDM2)
complex and leads to p53 accumulation and activation of apoptosis in HCT 116 cells. Here we show
the direct binding of PpIX to the N-terminal domain of p53. Furthermore, we addressed the induc-
tion of apoptosis in HCT 116 p53-null cells by PpIX and revealed interactions between PpIX and p73.
We propose that PpIX disrupts the p53/MDM2 or MDMX and p73/MDM2 complexes and thereby acti-
vates the p53- or p73-dependent cancer cell death.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The idea of highly selective and single-target-based treatments
emerged with the invention of personalized medicine and the
simultaneous twilight of classical, less individualized anticancer
treatments such as surgery or radiotherapy. Currently, in the ﬁeld
of oncology, the main emphasize is put on the tremendously selec-
tive, nearly non-toxic anticancer approaches in curing the so-called
‘plaque of the 20th century’ – cancer.
Due to its pro-apoptotic potential in tumors, p53 is regarded as a
tumor suppressor protein with still not fully disclosed cellular
functions. The search for similar proteins succeeded in the discoverychemical Societies. Published by E
ulinic acid; FP, ﬂuorescence
urine double minute 2; N,
ylamide gel electrophoresis;
and induction of tumor cells
acka-Pankau).
iology, Karolinska Institutet,
launching during postdoctoralof a sub-group of proteins called p53 family members, which
constitutes of p53 itself, p73 and p63 [1,2]. Similar to p53, p73 acts
as a tetrameric tumor suppressor by transcriptional regulation of
its target genes [3,4].
Photodynamic therapy (PDT) of cancer aims at the selective
elimination of tumor cells by the light-activated photosensitizing
agent previously accumulated in cancer cells. The activated drug,
the photosensitizer, generates singlet oxygen species via the en-
ergy transfer in type II photoreaction, which in consequence leads
to cancer cell death. However, the molecular mechanism of cancer
cell death due to PDT remains unclear [5,6]. Among the photosen-
sitizers studied, porphyrins manifest the lowest toxicity and have
shown the most promising clinical results. Unfortunately, their dis-
advantage is a tendency to aggregate, which signiﬁcantly lowers
the singlet oxygen quantum yield. Therefore, the most promising
strategy nowadays, and the ﬁrst pro-drug approach applied in
PDT, is the endogenous production of PpIX from its natural precur-
sor 5-aminolevulinic acid (5-ALA) [6].
Small molecules are recognized as highly potent therapeutics,
of which the p53 activators play an outstanding role. Some of these
molecules are in clinical trials and have shown an induction of
p53-dependent cancer cell death, with very little or no effect on
normal cells [7,8].lsevier B.V. All rights reserved.
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sors directly, e.g., Fhit or p53 [9,10]. Our previous study revealed a
novel action of PpIX, which is induction of apoptosis in human co-
lon cancer cells HCT 116 without light excitation [8]. Interestingly,
ﬂuorescent correlation spectroscopy showed direct binding of PpIX
to wtp53, which could explain the disruption of the p53/murine
double minute 2 (MDM2) complex in cells and induction of cancer
cell apoptosis. Nevertheless, the exact mechanism of p53 targeting
remains unclear as well as the induction of apoptosis in p53-deﬁ-
cient HCT 116 cells. In the present study we attempt to clarify this
phenomenon by investigating the direct interactions between the
N-terminal regulatory domains of p53 and p73 using several bio-
physical techniques. The obtained results indicate that protopor-
phyrin IX targets puriﬁed p53 and p73 proteins with the Kd of
approximately 0.5 lM. Our results suggest that both, p53 and
p73 might be regulated in cells by direct interactions with PpIX,
which might enhance cell apoptosis due to porphyrin-mediated
photodynamic treatment.
2. Material and methods
2.1. Plasmids and constructs
pGEX-2T-Np53 and pGEX-2T-tNp53 constructs encoding N-
terminal domain of p53 (Np53, 1–100 aa) and truncated
N-terminal domain of p53 (tNp53, 2–63 aa) were kindly provided
by Prof. Galina Selivanova (Karolinska Institute). pGEX-2T-Np73
and pGEX-2T-tNp73 constructs were obtained by cloning of frag-
ments encoding N-terminal domain of p73 (Np73, 1–116 aa) and
truncated N-terminal domain of p73 (tNp73, 1–54 aa) ampliﬁed
from human wild-type p73 cDNA into pGEX-2T expression vector
(GE Healthcare).
2.2. Expression and puriﬁcation of fusion proteins
Escherichia coli BL21(DE3) strains carrying the pGEX-2T-Np53,
pGEX-2T-tNp53 and pGEX-2T-tNp73 constructs and E. coli TOP10F0
carrying the pGEX-2T-Np73 construct were grown for 16 h in LB
medium (200 lg ampicillin/ml). Afterwards, the cultures were
inoculated into fresh LB medium and grew under standard condi-
tions to OD600 0.6. The expression of GST, GST-Np53, GST-tNp53,
GST-Np73 and GST-tNp73 proteins was induced by the addition
of 0.5 mM IPTG (Sigma). After 4 h of cultivation cells were har-
vested by centrifugation (4000 rpm, 15 min) and cell pellet was
frozen at 20 C.
Puriﬁcation of GST-Np53 and GST-tNp53 fusion proteins
was performed as described previously [18]. For puriﬁcation of
GST-Np73 and GST-tNp73 fusion proteins, 1 g of the bacterial
wet weight was resuspended in 10 ml of ice-cold STE buffer
(50 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM DTT,
0.025% Np40) with addition of leupeptin (1 lg/ml) and lysed with
1 mg/ml lysozyme for 30 min on ice. The batch puriﬁcation was
performed on Glutathione Sepharose™ 4B (GE Healthcare) with
1.5 h of incubation with shaking with bacterial lysate, two subse-
quent rinses with PBS (10 and 20 min) and two elutions (2 h and
overnight) with elution buffer (50 mM Tris pH 8.0, 150 mM NaCl,
1 mM DTT, 0.025% Np40, 1.5 mg/ml reduced glutathione).
2.3. Chemicals and reagents
Protoporphyrin IX (PpIX) was purchased from (Sigma–Aldrich,
Germany), reconstituted in 100% DMSO (Sigma–Aldrich) at 1 mM
concentration and stored at room temperature in dark. The con-
centration of the sensitizer was determined from molar extinction
coefﬁcient which was previously estimated for 100% DMSO as asolvent. Dextran blue (Sigma–Aldrich) was dissolved in standard
PBS buffer to 10 lM concentration and used as the column void
volume marker for gel ﬁltration on Sepharose Cl-4B (Pharmacia).
Human serum albumin (HSA, Sigma–Aldrich) and apotransferrin
(APO, Sigma–Aldrich) were resuspended in PBS to concentrations
75 lM and 100 lM, respectively. Non-denaturating gel molecular
weight marker was purchased from Sigma–Aldrich. The protein
size marker was separated according to the size and charge of
the proteins included.
2.4. Detection of protein-PpIX complexes in polyacrylamide gels
Prior to separation the samples of proteins (12.5 lM or 25 lM)
and PpIX (25 or 50 lM) were pre-incubated in buffer B (50 mM
Hepes pH 6.8, 150 mM NaCl, 35% glycerol) 30 min/37 C in dark.
After electrophoresis in standard 6% polyacrylamide gel under
non-denaturing conditions the ﬂuorescence of PpIX was detected
by the detection System I [9,11,12].
In the staining experiment the investigated proteins (12.5 lM
or 25 lM) were separated in the 6% polyacrylamide gel under
non-denaturing conditions and then the gel was incubated with
shaking in a water solution of PpIXNa (Sigma–Aldrich) (25 lM)
for 30 min in dark. After this time the gel was destained in several
runs of washes in ddH2O in dark (60 min) and the ﬂuorescence of
PpIX was detected every 20 min with detection System I.
2.5. Detection of protein-PpIX complexes by size exclusion
chromatography
Samples of PpIX (15 lM) with or without proteins (12.5 lM) in
degassed buffer A containing 1.75% glycerol were incubated
30 min/37 C in dark and separated on equilibrated Sepharose
CL-4B column (1 cm/6 cm). The samples were eluted with de-
gassed buffer A. Fractions (50 ll) were collected to a 96-well black
plate and the PpIX ﬂuorescence was measured in a microplate
reader Victor (Perkin–Elmer EG&G Wallac, USA) excitation
405 nm/emission 580 nm). The protein content was estimated by
means of standard Bradford assay.
2.6. Fluorescence polarization measurements
Emission spectrum of the 2 lM solution of PpIX in buffer A was
detected by the Perkin–Elmer Luminescence Spectrometer LS 50 B
under the excitation/emission wavelength 405/620 nm (15.0 nm
slit). For the measurements of ﬂuorescence polarisation, the
1.25 lM solution of PpIX in buffer A and the 10 lM proteins were
used. The degree of polarization of ﬂuorescence (P) of free and pro-
tein-associated PpIX was deﬁned in the way described previously
[10,12]. The controls constituted of human serum albumin and
GST.
2.7. Statistical analysis
The statistical signiﬁcance of results was calculated by a para-
metric Student’s t-test (for variances Fisher–Snedecor’s test was
used and the normality was assessed with the Shapiro–Wilk’s test).
p 6 0.05 values were considered statistically signiﬁcant.
3. Results
3.1. Protoporphyrin IX co-migrates with the N-terminal domain of p53
as detected in ﬂuorescent band shift assay
We have previously reported that protoporphyrin IX binds
wild-type p53 (wt-p53) in vitro as estimated by ﬂuorescent
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wt-p53 protein, as well as the N-terminal region, namely Np53
(1–100 aa) and tNp53 (2–63 aa) in two-site ELISA assay [10]. Fur-
thermore, our previous ﬁndings revealed the release of p53 from
MDM2 upon PpIX treatment of HCT116 colon carcinoma cells. In
the present study we prove, with the use of ﬂuorescent band shift
assay based on polyacrylamide gel electrophoresis (PAGE), that
PpIX targets the N-terminal region of p53. Fig. 1A shows the
co-migration of PpIX with Np53 and tNp53 proteins as evidenced
by the presence of a ﬂuorescent signal corresponding to protein-
associated protoporphyrin IX. This is in agreement with the
migration pattern of these proteins presented in the right panelFig. 1. (A) N-terminal domain of p53 binds protoporphyrin IX in vitro as detected in ﬂuor
a 6% polyacrylamide gel under non-denaturing conditions as described in Materials and m
incubated at 37 C/30 min and separated by PAGE. Lane 1 – apotransferrin (12.5 lM);
(12.5 lM) + PpIX; lane 5 – GST (25 lM); lane 6 – GST (25 lM) + PpIX; lane 7 – Np53 (
(25 lM) + PpIX. Shown are representative data of three independent experiments. (Pane
Np53 in vitro. Samples containing 12.5 and 25 lM proteins were separated in standard 6%
25 lM PpIXNa for 30 min as described in details in Materials and methods. The ﬂuoresce
migration pattern was estimated by coomassie staining (panel b). Lane 1 – HSA (12.5 lM
Protoporphyrin IX binds to the truncated (tN) and full (N) N-terminal domains of p53 in v
PpIX (15 lM) were incubated 37 C/30 min and separated on Sepharose CL-4B as descri
Bradford assay and the ﬂuorescence was measured at excitation 405/emission 580 nm w
are representative data of three independent experiments. Solid line – ﬂuorescence proﬁ
containing tNp53 and PpIX (C upper panel) elution proﬁles of a sample containing apotof Fig. 1A. The controls constituted of human serum albumin, a
known blood carrier of multiple drugs [11–14] and GST. Of notice,
only background ﬂuorescence is registered for the negative con-
trols, namely apotransferrin and GST, which excludes the proba-
bility of the GST modiﬁcation to inﬂuence the PpIX binding to
the investigated proteins. Full-length N-terminal domain of p53
seems to associate stronger to PpIX when compared to tNp53
as estimated by the band density measurements (0.796 ± 0.046
versus 0.442 ± 0.060 when normalized to the negative control).
It might be explained by the difference in molecular weights
between Np53 and tNp53 caused by the presence of proline-rich
region in Np53 structure.escent band shift assay. (Panel a) Detection of ﬂuorescent protein-PpIX complexes in
ethods. Concisely, samples containing 12.5 or 25 lM proteins and 50 lM PpIX were
lane 2 – apotransferrin (12.5 lM) + PpIX; lane 3 – HSA (12.5 lM); lane 4 – HSA
25 lM); lane 8 – Np53 (25 lM) + PpIX; lane 9 – tNp53 (25 lM); lane 10 – tNp53
l b) Protein migration pattern upon coomassie staining. (B) PpIX sodium salt targets
polyacrylamide gel under non-denaturating conditions and subject to staining with
nce of PpIXNa was registered after 60 min wash with ddH2O (panel a). The protein
); lane 2 – GST (25 lM); lane 3 – Np53(25 lM); lane 4 – tNp53(25 lM). (C and D)
itro as detected by gel ﬁltration. The samples of investigated proteins (12.5 lM) and
bed in Materials and methods. The protein content was estimated by the standard
avelength. V0 was estimated by ﬁltration of 1.5 lM solution of dextran blue. Shown
le; dashed line – protein elution proﬁle: (C lower panel) elution proﬁles of a sample
ransferrin and PpIX (D) elution proﬁles of a sample containing Np53 and PpIX.
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To conﬁrm the in vitro targeting of p53 N-terminal region by
PpIX we performed the gel staining with separated proteins of
interest with the use of aqueous solution of PpIX sodium salt.
Brieﬂy, the investigated proteins were separated in standard 6%
polyacrylamide gel under non-denaturating conditions. After elec-
trophoresis the gel was subject to staining using 25 lM PpIXNa.
The ﬂuorescence of PpIXNa was registered before the staining to
assess any endogenous ﬂuorescence of the investigated proteins
(not shown) and after 60 min wash with ddH2O (Fig. 1B, panel a).
In the end, the protein migration pattern was estimated by
Coomassie staining (Fig. 1B, panel b). The results pointed to the
binding of PpIX to both tN and Np53 proteins. Only background
binding was registered for GST. The highest ﬂuorescent signal
was detected for HSA, a positive control, which has a high afﬁnity
to porphyrinogenic compounds [13,14]. No signiﬁcant difference in
the afﬁnity to PpIX has been observed for tN and Np53.
3.3. Co-elution of PpIX with p53 proteins in gel ﬁltration study
Another approach to investigate protein binding to a ﬂuorescent
ligand is size-exclusion chromatography, which we successfully
applied in our previous reports [10,12]. To further assess the bind-
ing capacity of PpIX to p53 we performed gel ﬁltration using Se-
pharose CL-4B. PpIX itself eluted almost in the void volume of
the column (V0) which is in agreement with our previous results
indicating that under given conditions PpIX forms aggregates.
Upon incubation with p53 proteins PpIX was found to be pro-
tein-associated as expressed by the overlapping ﬂuorescent and
protein elution proﬁles (Fig. 1C and D). In consistence, no complex
was detected for the negative control, namely, apotransferrin
(Fig. 1C upper panel).
3.4. PpIX targets the p53 homolog, p73
As mentioned above, our ﬁndings prompted us to gain insight
into the issue of apoptosis induction upon PpIX treatment of HCT
116 colon cancer cells lacking p53. We focused our efforts on the
p53 family member, p73 since it is rarely mutated in cancers,
which makes it a promising candidate for targeted anti-cancer
therapies. The high structural and functional homology between
p53 and p73 suggests that PpIX may also target p73. We cloned
and puriﬁed GST fusion proteins, tNp73 and Np73, which we used
for in vitro assessing of p73/PpIX complex formation.
Fluorescent band shift assay was performed using two concen-
trations of PpIX – 50 and 100 lM (Fig. 2A and B). Both proteins co-
migrated with PpIX which points to their direct interactions with
the ﬂuorescent dye. Further, gel staining in PpIXNa solution re-
vealed that PpIX indeed targets p73 proteins (Fig. 2C). However,
no signiﬁcant difference was noticed in the intensity of the ﬂuores-
cent signal, which might suggest the same afﬁnity of PpIX to all
investigated proteins. Additionally, gel-exclusion chromatography
conﬁrmed our observations that PpIX targets p73 N-terminal re-
gion but not GST in vitro (Fig. 2D and E). Taken together using three
independent approaches we show that PpIX associates with p53
and p73 in vitro. To further clarify this, we applied yet another
technique based on the degree of polarization of ﬂuorescence (P)
of protein-associated PpIX when compared to free PpIX.
3.5. Fluorescence polarization reveals PpIX binding to p53 and p73
We measured the ﬂuorescence polarization ratio (FP) of free
PpIX which remains almost unchanged upon dilution with the pro-
teins’ elution buffer (control). Upon addition of the investigated
proteins to the PpIX solution a signiﬁcant increase in FP valuewas registered (Fig. 2F). The addition of GST-Np53 and GST-Np73
induced 2-fold increase in FP value, corresponding to the increase
caused by the addition of HSA. Remarkably, addition of both
GST-tNp53 and GST-tNp73 to PpIX solution produced a 1.5-fold
increase in FP value. This is in agreement with the differences in
the molecular size of the investigated proteins. The larger in size
the protein of interest, upon association with PpIX induces higher
change in the degree of ﬂuorescence polarization. For GST protein
no signiﬁcant increase in FP value was observed, which indicates
that PpIX does not interact with glutathione transferase itself
which is in agreement with the results from previous experiments
based on size exclusion chromatography.
In conclusion, using three independent biophysical methods we
conﬁrmed the binding of PpIX, a sensitizer used in photodynamic
therapy of cancer, to N-terminal domains of p53 as well as its
homolog p73. Such binding might be responsible for the previously
reported disruption of the p53/MDM2 complexes [10] and also
welcomes the hypothesis of potent putative regulation of p73
proapoptotic function in tumors by PpIX (Fig. 3).4. Discussion
The strategy to combat cancer is still not set. Presently the ef-
forts are mainly focused on the small molecules, which target a
certain pathway/protein selectively in cancer cells exhibiting no
or very low effect in normal tissues [7,8,15]. During the past
10 years, the development of low molecular weight activators of
p53 has been a priority. Due to the well established status of p53
in different types of human cancers, the therapeutic strategy seems
to be quite straightforward. However, despite extensive research
neither nutlin nor reactivation of p53 and induction of tumor cells
apoptosis (RITA), known wt-p53 activators, reached the phase of
clinical trials yet. What is more, restoration of functional p53 in
cancer cells lacking its expression is still a tantalizing task. There-
fore, identiﬁcation of new targets and their inducers might provide
a valuable approach for the treatment of cancers arising from the
loss of p53 function.
In this study, we investigated the in vitro targeting of p53 as
well as p73 by the only available endogenous photosensitizer –
protoporphyrin IX. PpIX is currently in clinical use in form of its
cellular precursor – aminolevulinic acid (e.g. Metvix). We have
previously found that PpIX targets wt-p53 in vitro and disrupts
the p53/MDM2 complex as assessed by immunoprecipitation assay
[10]. We reasoned that PpIX might associate with the N-terminal
regulatory domain of p53. This hypothesis was conﬁrmed in this
study by applying four biophysical methods, which clearly indicate
the formation of a p53/PpIX complex. Even thought the ﬂuorescent
signal for p53/PpIX was lower when compared to the positive con-
trol (HSA), it can be explained by the fact that albumin is a blood
transporter protein with the average afﬁnity constant of 6 lM to
PpIX [16].
Data described in this study together with our previous results
[10] allow us to conclude that PpIX, by direct binding to the
N-terminal region of p53, might release p53 from the regulatory
complex with MDM2 E3 ligase which in consequence leads to
the induction of p53-dependent tumor cell apoptosis.
We next focused on the p53 homolog, p73. As p73 is similar to
p53 in structure and function, we presumed that it might undergo
similar regulation by PpIX. p73 also binds to MDM2, but the bind-
ing does not result in p73 degradation in ubiquitin dependent
manner [17]. Nevertheless, p73/MDM2 interaction is still sufﬁcient
to impede p73 transcriptional function. The p53 activator nutlin
has been shown to activate p73 in cancer cells [18,19]. Nutlin
treatment was shown to induce accumulation of p73 and
transcription factor E2F1 with a subsequent induction of the
Fig. 2. (A and B) N-Terminal region of p73 binds protoporphyrin IX in vitro as detected in ﬂuorescent band shift assay. (Panel a) Detection of ﬂuorescent complexes between
tNp73 (A) and Np73 (B) in a 6% polyacrylamide gel under non-denaturing conditions as described in Materials and methods. Concisely, samples containing 12.5 or 25 lM
proteins and 50 lM or 100 lM PpIX were incubated at 37 C/30 min and separated by PAGE. PpIX ﬂuorescence was detected (a) as well as protein migration pattern (panel b).
(A) Lane 1 –HSA (25 lM); lane 2 – HSA (25 lM) + PpIX (50 lM); lane 3 – GST (25 lM); lane 4 – GST (25 lM) + PpIX (50 lM); lane 5 – tNp73 (25 lM); lane 6 – tNp73
(25 lM) + PpIX (50 lM); lane 7 – tNp73 (25 lM); lane 8 – tNp73 (25 lM) + PpIX (100 lM). (B) Lane 1 – HSA (12.5 lM); lane 2 – HSA (12.5 lM) + PpIX (50 lM); lane 3 – GST
(25 lM); lane 4 – GST (25 lM) + PpIX (50 lM); lane 5 – Np73 (25 lM); lane 6 – Np73 (25 lM) + PpIX (50 lM); lane 7 – Np73 (25 lM); lane 8 – Np73 (25 lM) + PpIX
(100 lM). Shown are representative data of three independent experiments. (C) PpIX sodium salt targets N-terminal domain of p73 in vitro. Samples containing 12.5 and
25 lM proteins were separated in standard 6% polyacrylamide gel under non-denaturating conditions and subject to staining with 25 lM PpIXNa for 30 min as described in
details in Materials and methods. The ﬂuorescence of PpIXNa was after 60 min wash with ddH2O (panel a). The protein migration pattern was estimated by Coomassie
staining (panel b). Lane 1 – HSA (12.5 lM); lane 2 – GST (25 lM); lane 3 – tNp73(25 lM); lane 4 – Np73(25 lM). (D and E) Protoporphyrin IX binds to the truncated (1C) and
full (1D) N-terminal domain of p73 in vitro as detected by gel ﬁltration. The samples of investigated proteins (12.5 lM) and PpIX (15 lM) were incubated 37 C/30 min and
separated on Sepharose CL-4B as. The protein content was estimated by the standard Bradford assay and the ﬂuorescence was measured at excitation 405/emission 580 nm
wavelength. V0 was estimated by ﬁltration of 1.5 lM solution of dextran blue. Shown are representative data of three independent experiments. Solid line – ﬂuorescence
proﬁle; dashed line – protein elution proﬁle: (D lower panel) elution proﬁles of a sample containing tNp73 and PpIX (D upper panel) elution proﬁles of a sample containing
GST and PpIX (E) elution proﬁles of a sample containing Np73 and PpIX. (F) Targeting of investigated N-terminal proteins by PpIX as assessed by ﬂuorescence polarization.
Fluorescence polarization of samples containing PpIX alone (2 lM) and PpIX with investigated proteins (10 lM) was registered as described in Materials and methods. The
data are the representative of three independent experiments performed in triplicates.
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Fig. 3. A schematic representation of the putative induction of p53 and p73 tumor
suppressor by protoporphyrin IX in cancer cells. Upon MDM2 overproduction p53
and p73 are constantly inhibited. Association of these proteins with PpIX leads to
the disruption of p53/MDM2 or p73/MDM2 complexes and their transcriptional
activity is restored. This is observed as a massive cancer cell death upon PpIX
treatment.
260 A. Sznarkowska et al. / FEBS Letters 585 (2011) 255–260p53-upregulated modulator of apoptosis – PUMA [19]. In the re-
cent work Busuttil et al. showed that induction of Bim by p73 ac-
counts for the induction of p73-dependent apoptosis in activated T
cells with chalcone-inhibited MDM2 [20]. Providing PpIX disrupts
p73/MDM2 complex formation, it seems worthwhile to investigate
whether p73-induced apoptosis might be in this case as well Bim-
dependent.
In conclusion,wehave shown for theﬁrst time that protoporphy-
rin IX targets the N-terminal domain of two functionally and struc-
turally homologous proteins – p53 and p73 in vitro. The most
sensitive of the methods used, ﬂuorescence polarization, indicated
that deletion of amino acids encoding polyproline region of Np53
andNp73 slightly reduces the binding of PpIX to N-terminal domain
of these proteins, though this issue should be investigated further.
Our ﬁndings are crucial for the disclosure of the molecular
mechanisms underlying cancer cell death due to PDT. We assume
that PpIX by direct binding to N-terminal regions of p53 and p73
can release these powerful tumor suppressors from e.g. MDM2
inhibition which further might lead to tumor cell apoptosis. To-
gether with the oxidative stress generated by the light-excited
PpIX, the reactivation of tumor suppressors can promote a massive
cancer cell death upon photodynamic treatment.
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